SCHEMBL4450062

SCHEMBL4450062

S=C(N/N=C/c1ccc(-c2ccc(Cl)cc2)o1)NC1CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.59
WDR77 Q9BQA1 1/20 0.59
MAPT P10636 7/20 0.56
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 5/20 0.56
NPC1 O15118 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
RAB9A P51151 2/20 0.56
PHGDH O43175 4/20 0.52
HPGD P15428 4/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
NPSR1 Q6W5P4 3/20 0.52
LMNA P02545 3/20 0.52
PKM P14618 2/20 0.52
ALOX12 P18054 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
POLB P06746 1/20 0.51
HSP90AA1 P07900 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4450070 1.00 PRMT5 (0.59) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4461760 0.86 KDM4E (0.70) MAPTKDM4EALDH1A1NPC1L3MBTL1
SCHEMBL4461766 0.86 KDM4E (0.70) MAPTKDM4EALDH1A1NPC1L3MBTL1
SCHEMBL13611615 0.83 MAPT (0.72) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4462860 0.83 MAPT (0.72) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL13886804 0.81 MAPT (0.58) MAPTKDM4EALDH1A1NPC1L3MBTL1
SCHEMBL20115492 0.80 STS (0.71) MAPTKDM4ENPC1L3MBTL1RAB9A
SCHEMBL21292821 0.80 STS (0.71) MAPTKDM4ENPC1L3MBTL1RAB9A
SCHEMBL4326738 0.80 MAPT (0.78) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4326742 0.80 MAPT (0.78) PRMT5WDR77MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PRMT5 4357/4885WDR77 3480/4885MAPT 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.